Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 CYT997 monotherapy in relapsed or refractory multiple myeloma
ACTRN12607000584437Phase 2Completed
- Sponsor
- YM BioSciences
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Lexibulin in multiple myeloma (MM), sponsored by YM BioSciences. Primary endpoint: Overall response rate. Started Dec 2007; status: completed.
02
Drugs
Lexibulin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12607000584437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000584437.